Navigation Links
Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
Date:5/3/2012

. In keeping with the company commitment to do the most good for the most people, Boehringer Ingelheim works hard to ensure its medicines are accessible to everyone who needs them, including senior citizens and families on limited incomes. The Boehringer Ingelheim Cares Foundation Patient Assistance Programs (BI-PAP) make Boehringer Ingelheim medicines available free of charge to patients who are without pharmaceutical insurance coverage, and who meet certain household income levels.

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion (13.2 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
4. Boehringer Ingelheim Unveils Diabetes Pipeline
5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 Arbor Pharmaceuticals, LLC. ... Global Markets Direct,s, ,Arbor Pharmaceuticals, LLC. - ... of the Arbor Pharmaceuticals, LLC.,s pharmaceutical research and ... on the current therapeutic developmental pipeline of Arbor ... stages, therapeutics assessment by drug target, mechanism of ...
(Date:9/30/2014)... DENVER , Sept. 30, 2014  According ... "the world of cancer clinical trials is going ... clinical trials and the work of the current ... these types of ,next generation, clinical trials, which ... tomorrow."  The company has been ...
(Date:9/30/2014)... , Sept. 30, 2014 A study ... (OCT), offered a new look at the composition of ... how physicians understand and treat the disease, a leading ... at Baptist Health Lexington between September 2010 and May ... the Journal of the American College of Cardiology ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
... Combination with CRESTOR (rosuvastatin calcium) Demonstrates Similar Lipid Effects ... ... Population, SAN FRANCISCO, June 7 ... type 2 diabetes,that were enrolled in a Phase III study showed ...
... the ADA,s Annual Scientific Sessions, SAN FRANCISCO, ... of the dose-finding study for its new,injectable diabetes ... American Diabetes Association,s (ADA) 68th Annual Scientific Sessions,meeting ... that AVE0010 was well tolerated and significantly,improved glycemic ...
Cached Medicine Technology:Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 2Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 3Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 4New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 2New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 3New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 4
(Date:10/1/2014)... Long-acting insulin is safer and more effective than ... according to new research published in the ... and twice-daily doses of both long- and intermediate-acting ... , "In patients with Type 1 diabetes, we ... insulin when it came to controlling blood sugar, ...
(Date:10/1/2014)... holiday gift ideas? Éminence Organic Skin Care, the leader in ... season. Starting October 1st 2014, new spa gift sets are ... from two luxury skin care gift sets made from the ... to deliver whole body beauty. , The luxurious Body ... formulated to suit all skin types and will tick all ...
(Date:10/1/2014)... To help raise awareness about women’s health, leading Detroit ... several tips for women looking to live a healthier and ... should start each day with meditation, prayer and breathing exercises. ... yourself for the rest of the day and prevent the ... and fitness tips include:, -Drink half your weight in ounces ...
(Date:9/30/2014)... proactive about potential disease outbreaks like Ebola and establish ... Editorial in the October issue of Australian and ... from Monash University and Heath Kelly from the Australian ... , "Australia would do well to heed the lessons ... a consistent and outward looking response," the authors said. ...
(Date:9/30/2014)... conceived either less than one year or more than five ... increased risk for autism, a new study suggests. However, ... that the research can,t prove that birth spacing has any ... that parents understand that the odds for autism are still ... apart," said outside expert Dr. Andrew Adesman. He is chief ...
Breaking Medicine News(10 mins):Health News:Long-acting insulin is safer, more effective for patients with Type 1 diabetes 2Health News:Éminence Organic Skin Care Launches Limited Edition Spa Gift Sets for the Holiday Season 2Health News:Éminence Organic Skin Care Launches Limited Edition Spa Gift Sets for the Holiday Season 3Health News:In Recognition of National Women’s Health and Fitness Day, Cutler Integrative Medicine Details Tips for Living a Healthier and Happier Life 2Health News:Spacing Between Sibling Births Tied to Autism Risk in Study 2
... food to infants less than six months old is not ... allergies later and new moms should rather breastfeed them exclusively, ... avoided for the first six months, and certain items like ... until even later, according to the American College of Allergy, ...
... Consuming naturally occurring compounds in cocoa could improve ... also help blood flow// in menopausal women with ... and gives us new insights into how cocoa ... ways not previously known,' said Harold Schmitz, PhD, ...
... embryo formation has been discovered in malignant melanoma cells ... Scientist discovered this protein called Nodal by injecting malignant ... were able to induce abnormal embryonic skull and backbone ... published in online issue of the journal, Nature Medicine. ...
... the researchers at the University of Florida, Gainesville, mice based ... treat hereditary diseases of the heart.// , This ... with muscular dystrophy that damages the heart. The findings, published ... the way for studies in humans that could begin as ...
... Health service helpline NHS 24 has been criticized severely because a ... old lady.// ,Retired nurse Mary Smith, 87 had an ... helpline twice but the nurse curtly replied that she could not ... for a GP to attend to her. Then when the GP ...
... Hyderabad-based Aurobindo Pharma Ltd today said it has ... fixed drug combination product used for anti-HIV treatment. ... contains Lamivudine 150mg+2idovudine300mg tablets co-packaged with Abacavir 300mg ... ,This combination pack enhances convenience, is cost-effective ...
Cached Medicine News:Health News:Protein Involved In Embryo Formation Found In Malignant Cells 2Health News:Gene Therapy Technique for Inherited Heart Problems in The Pipeline 2Health News:Gene Therapy Technique for Inherited Heart Problems in The Pipeline 3Health News:Gene Therapy Technique for Inherited Heart Problems in The Pipeline 4
DNA/RNA preparation in 8-multi channels...
... units with hydrophobic PTFE membranes,Millex filter ... ideal for the sterilizing filtration of ... and for sterilizing or clarifying organic ... filter units are available with different ...
... Bottled Water, The Simplicity personal water system ... currently use bottled water. In addition to ... store bottled water, your laboratory applications may ... be absorbed from containers and cause water ...
... of Type I ultrapure water, , Ultrapure ... System is designed to provide the "final ... by reverse osmosis, distillation or deionization. Super-Q ... which exceeds Type I ASTM/CAP/NCCLS specifications.,The Super-Q ...
Medicine Products: